/Quest%20Diagnostics%2C%20Inc_%20inside%20office-by%20Kit%20Leong%20via%20Shutterstock.jpg)
Valued at a market cap of $17.1 billion, Quest Diagnostics Incorporated (DGX) is a leading provider of diagnostic testing and services in the United States and internationally. Based in Secaucus, New Jersey, the company delivers routine, advanced clinical, and anatomic pathology testing under brands such as Quest Diagnostics, AmeriPath, and Dermpath Diagnostics.
Companies valued at $10 billion or more are generally considered "large-cap" stocks, and Quest Diagnostics fits this criterion perfectly. Focused on accelerating growth and operational excellence, Quest employs strategic approaches like disease-focused esoteric testing, hospital partnerships, and enterprise IT enhancements. It supports physicians, hospitals, insurers, and patients through its extensive network of laboratories, patient service centers, and mobile phlebotomy services.
